Literature DB >> 19910293

Determinants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy.

Johanna A Miettinen1, Kari Ylitalo, Pirjo Hedberg, Jari Jokelainen, Kari Kervinen, Matti Niemelä, Marjaana Säily, Pirjo Koistinen, Eeva-Riitta Savolainen, Heikki Ukkonen, Mikko Pietilä, K E Juhani Airaksinen, Juhani Knuuti, Olli Vuolteenaho, Timo H Mäkikallio, Heikki V Huikuri.   

Abstract

OBJECTIVE: To assess the determinants of functional recovery in patients with ST-elevation myocardial infarction (STEMI) treated initially with thrombolysis, followed by percutaneous coronary intervention and intracoronary injection of bone marrow-derived stem cells (BMC).
DESIGN: A randomised, placebo-controlled, double-blind study (substudy of FINCELL).
SETTING: Two tertiary cardiac centres. PARTICIPANTS: 78 patients with STEMI randomly assigned to receive either intracoronary BMC (n=39) or placebo (n=39) into the infarct-related artery.
INTERVENTIONS: Thrombolysis a few hours after symptom onset, percutaneous coronary intervention and intracoronary injection of BMC 2-6 days later. MAIN OUTCOME MEASURES: Efficacy of the BMC treatment was assessed by measurement of the change of global left ventricular ejection fraction (LVEF) from baseline to 6 months after STEMI. Various predefined variables (eg, the levels of certain natriuretic peptides and inflammatory cytokines) were analysed as determinants of improvement of LVEF.
RESULTS: In the BMC group, the most powerful determinant of the change in LVEF was the baseline LVEF (r=-0.58, p<0.001). Patients with baseline LVEF at or below the median (< or = 62.5%) experienced a more marked improvement in LVEF (+12.7 + or - 12.5 %units, p<0.001) than those above the median (-0.8 + or - 6.3 %units, p=0.10). Elevated N-terminal probrain natriuretic peptide (p<0.001) and N-terminal proatrial natriuretic peptide (p=0.052) levels were also associated with improvement in LVEF in the BMC group but not in the placebo group.
CONCLUSIONS: The global LVEF recovers most significantly after intracoronary infusion of BMC in patients with the most severe impairment of LVEF on admission. The baseline levels of natriuretic peptides seem also to be associated with LVEF recovery after BMC treatment. Trial registration ClinicalTrials.gov number, NCT00363324.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910293     DOI: 10.1136/hrt.2009.171694

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

Review 1.  Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.

Authors:  Sangho Lee; Young-Sup Yoon
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

2.  Meta-Analyses of Human Cell-Based Cardiac Regeneration Therapies: Controversies in Meta-Analyses Results on Cardiac Cell-Based Regenerative Studies.

Authors:  Mariann Gyöngyösi; Wojciech Wojakowski; Eliano P Navarese; Lemuel À Moye
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

Review 3.  Imaging: guiding the clinical translation of cardiac stem cell therapy.

Authors:  Patricia K Nguyen; Feng Lan; Yongming Wang; Joseph C Wu
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

Review 4.  A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.

Authors:  Anita D Szady; Carl J Pepine; Shreela V Sharma; Christopher R Cogle; Emerson C Perin; Stephen G Ellis; Lemuel A Moyé
Journal:  Curr Atheroscler Rep       Date:  2013-08       Impact factor: 5.113

5.  Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Authors:  Jay H Traverse; Timothy D Henry; Stephen G Ellis; Carl J Pepine; James T Willerson; David X M Zhao; John R Forder; Barry J Byrne; Antonis K Hatzopoulos; Marc S Penn; Emerson C Perin; Kenneth W Baran; Jeffrey Chambers; Charles Lambert; Ganesh Raveendran; Daniel I Simon; Douglas E Vaughan; Lara M Simpson; Adrian P Gee; Doris A Taylor; Christopher R Cogle; James D Thomas; Guilherme V Silva; Beth C Jorgenson; Rachel E Olson; Sherry Bowman; Judy Francescon; Carrie Geither; Eileen Handberg; Deirdre X Smith; Sarah Baraniuk; Linda B Piller; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2011-11-14       Impact factor: 56.272

6.  Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.

Authors:  Mariann Gyöngyösi; Wojciech Wojakowski; Patricia Lemarchand; Ketil Lunde; Michal Tendera; Jozef Bartunek; Eduardo Marban; Birgit Assmus; Timothy D Henry; Jay H Traverse; Lemuel A Moyé; Daniel Sürder; Roberto Corti; Heikki Huikuri; Johanna Miettinen; Jochen Wöhrle; Slobodan Obradovic; Jérome Roncalli; Konstantinos Malliaras; Evgeny Pokushalov; Alexander Romanov; Jens Kastrup; Martin W Bergmann; Douwe E Atsma; Axel Diederichsen; Istvan Edes; Imre Benedek; Theodora Benedek; Hristo Pejkov; Noemi Nyolczas; Noemi Pavo; Jutta Bergler-Klein; Imre J Pavo; Christer Sylven; Sergio Berti; Eliano P Navarese; Gerald Maurer
Journal:  Circ Res       Date:  2015-02-19       Impact factor: 17.367

7.  Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.

Authors:  Sung-Whan Kim; Hyongbum Kim; Young-sup Yoon
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

8.  Effects of intracoronary injection of autologous bone marrow-derived stem cells on natriuretic peptides and inflammatory markers in patients with acute ST-elevation myocardial infarction.

Authors:  Johanna A Miettinen; Kari Ylitalo; Pirjo Hedberg; Kari Kervinen; Matti Niemelä; Marjaana Säily; Pirjo Koistinen; Eeva-Riitta Savolainen; Heikki Ukkonen; Mikko Pietilä; K E Juhani Airaksinen; Juhani Knuuti; Olli Vuolteenaho; Timo H Mäkikallio; Heikki V Huikuri
Journal:  Clin Res Cardiol       Date:  2010-10-17       Impact factor: 5.460

9.  Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Authors:  Jay H Traverse; Timothy D Henry; Carl J Pepine; James T Willerson; David X M Zhao; Stephen G Ellis; John R Forder; R David Anderson; Antonis K Hatzopoulos; Marc S Penn; Emerson C Perin; Jeffrey Chambers; Kenneth W Baran; Ganesh Raveendran; Charles Lambert; Amir Lerman; Daniel I Simon; Douglas E Vaughan; Dejian Lai; Adrian P Gee; Doris A Taylor; Christopher R Cogle; James D Thomas; Rachel E Olson; Sherry Bowman; Judy Francescon; Carrie Geither; Eileen Handberg; Casey Kappenman; Lynette Westbrook; Linda B Piller; Lara M Simpson; Sarah Baraniuk; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Daniel B Spoon; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

10.  Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells.

Authors:  Joseph C Poole; Arshed A Quyyumi
Journal:  Stem Cells Int       Date:  2013-04-28       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.